Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Wants More Analysis From BioMimetic On Augment Bone Graft

This article was originally published in The Gray Sheet

Executive Summary

Agency issues “not approvable” letter seeking more detailed analysis from the firm’s already-completed pivotal trial, but FDA is not asking for a new clinical study, BioMimetic stressed.

Advertisement

Related Content

BioMimetic Amends Augment Bone Graft PMA, Expects Approval By 2014
Research In Brief
FDA Panel Narrowly Supports BioMimetic's Augment Synthetic Bone Graft

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT030860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel